101,298 Shares in Twist Bioscience Corporation $TWST Purchased by Lord Abbett & CO. LLC

Key Points

• Lord Abbett & CO. LLC has acquired a new stake in Twist Bioscience, purchasing 101,298 shares valued at approximately $3.98 million, representing 0.17% ownership of the company.
• Twist Bioscience reported a quarterly EPS of ($0.47), outperforming analysts' estimates and generating revenue of $96.06 million, just above expectations.
• Brokerages maintain a generally positive outlook on Twist Bioscience, with a consensus rating of "Moderate Buy" and an average target price of $49.40.

Lord Abbett & CO. LLC acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 101,298 shares of the company's stock, valued at approximately $3,977,000. Lord Abbett & CO. LLC owned about 0.17% of Twist Bioscience as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of TWST. GAMMA Investing LLC increased its stake in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the last quarter. Deerfield Management Company L.P. Series C grew its holdings in Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after purchasing an additional 403 shares during the period. Summit Investment Advisors Inc. increased its position in Twist Bioscience by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock worth $283,000 after purchasing an additional 443 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC grew its stake in shares of Twist Bioscience by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 23,178 shares of the company's stock valued at $910,000 after buying an additional 612 shares during the period.

Analyst Ratings Changes

Several brokerages have commented on TWST. Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. JPMorgan Chase & Co. reduced their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a research note on Monday, August 4th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Stock Performance

NASDAQ:TWST traded up $0.0070 during mid-day trading on Thursday, hitting $26.4570. The stock had a trading volume of 627,601 shares, compared to its average volume of 1,193,948. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a 50 day simple moving average of $33.78 and a 200-day simple moving average of $36.75. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -18.26 and a beta of 2.36. Twist Bioscience Corporation has a 52 week low of $24.28 and a 52 week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at $23,093,164.32. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,089 shares of company stock valued at $217,117. Insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.